Skip to main content

Clinical Trials Using Autologous CD30CAR-CD28-CD3zeta-expressing T-Lymphocytes

Review the clinical trials studying autologous cd30car-cd28-cd3zeta-expressing t-lymphocytes on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-3 of 3

Genetically Engineered Cells (ATLCAR.CD30) for the Treatment of Patients with Refractory or Relapsed CD30+ Nonseminomatous Germ Cell Tumors
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Genetically Engineered Cells (ATLCAR.CD30 T Cells) for the Treatment of Relapsed or Refractory CD30 Positive Peripheral T Cell Lymphoma
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
ATLCAR.CD30.CCR4 with or without ATLCAR.CD30 in Treating Patients with Relapsed or Refractory CD30+ Hodgkin Lymphoma or Cutaneous T-cell Lymphoma
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina